Effectiveness of dexamethasone in preventing extubation failure in preterm infants at increased risk for airway edema.
We studied 50 preterm infants who had multiple or traumatic endotracheal intubations, or whose duration of endotracheal intubation was > or = to 14 days, and who were considered at high risk for airway edema. These infants were enrolled in a prospective, randomized, controlled clinical trial to assess whether prophylactic dexamethasone therapy would be effective in the prevention of postextubation stridor and respiratory distress. At study entry, both groups had similar weights, postnatal ages, methylxanthine use, ventilator settings, blood gas values, and pulmonary function test results (dynamic compliance, total respiratory resistance, tidal volume, peak-to-peak transpulmonary pressure, minute ventilation, and peak inspiratory and expiratory flow rates). Patients underwent blood gas studies, physical examinations, and pulmonary function testing at baseline (4 hours before extubation) and again 2 to 4 hours and 18 to 24 hours after extubation. Twenty-seven infants received dexamethasone, 0.25 mg/kg per dose, at baseline, and then every 8 hours for a total of three doses; 23 infants received saline solution at corresponding times. Eighteen to twenty-four hours after extubation, total pulmonary resistance increased by 225% from baseline in the control group compared with 33% in the dexamethasone group (p < 0.006), and the dexamethasone group had a greater tidal volume, a greater dynamic compliance, and a lower arterial carbon dioxide pressure. Of 23 control infants, 10 had postextubation stridor compared with 2 of 27 dexamethasone-treated patients (p < 0.006). Of the 23 control patients, 4 required reintubation compared with none of the treated group (p < 0.05). We conclude that the prophylactic use of corticosteroids for the prevention of postextubation stridor and respiratory distress is efficacious in low birth weight, high-risk preterm infants.
Couser
R J
RJ
Division of Neonatology, Minneapolis Children's Medical Center, Minnesota.
Ferrara
T B
TB
Falde
B
B
Johnson
K
K
Schilling
C G
CG
Hoekstra
R E
RE
D002245:Carbon Dioxide / Q000097:blood; D003907:Dexamethasone / Q000494:pharmacology / Q000627:therapeutic use*; D004487:Edema / Q000150:complications / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D007231:Infant, Newborn; D007442:Intubation, Intratracheal / Q000009:adverse effects*; D007818:Laryngeal Diseases / Q000150:complications / Q000453:epidemiology / Q000209:etiology*; D010100:Oxygen / Q000097:blood; D011446:Prospective Studies; D012119:Respiration / Q000187:drug effects; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D012135:Respiratory Sounds / Q000187:drug effects* / Q000209:etiology / Q000503:physiopathology; D012307:Risk Factors; D014133:Tracheal Diseases / Q000150:complications / Q000453:epidemiology / Q000209:etiology*; D017211:Treatment Failure
D002245:Carbon Dioxide; D003907:Dexamethasone; D010100:Oxygen